The posting uses the example of Frazier Healthcare Ventures, a Seattle, Washington-based firm that is focused exclusively on life sciences.

The veteran firm is noting that it will increase the percentage devoted to later stage deals at the expense of earlier stage deals, reflecting the general wariness of investing in high risk, early-stage medical technologies.